Scarica l'app Stockscreener
382.47
2.25%
-8.80
Dopo l'orario di chiusura:
383.00
0.53
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen (AMGN) Dips More Than Broader Market: What You Should Know - Yahoo! Finance Canada
Stock Traders Buy Large Volume of Put Options on Amgen (NASDAQ:AMGN) - MarketBeat
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study - The Globe and Mail
Amgen’s New Repatha Plaque Trial: What Investors Should Watch - TipRanks
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen at Wells Fargo 21st Annual Healthcare Conference: growth broadens By Investing.com - Investing.com India
Amgen stock dips as HSBC cuts rating and trims price target - ad-hoc-news.de
Amgen (AMGN) Stock Looks Cheap Relative To Fair Value - simplywall.st
HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445 - marketscreener.com
Amgen Stock: Buy The Novartis-Driven Selloff (Rating Upgrade) (NASDAQ:AMGN) - Seeking Alpha
Sequoia Financial Advisors LLC Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
National Pension Service Has $465.74 Million Stake in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Has $33.69 Million Holdings in Amgen Inc. $AMGN - MarketBeat
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review By Investing.com - Investing.com South Africa
HSBC downgrades Amgen stock rating to Hold on valuation - Investing.com
HSBC downgrades Amgen stock rating to Hold on valuation By Investing.com - Investing.com Canada
Amgen stock heads into the open after a 10.1 percent drop - ad-hoc-news.de
Amgen’s Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PR Newswire
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - The Pharma Letter
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - ad-hoc-news.de
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
Baird Financial Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Amgen stock heads into the open after a 10.1% drop - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Canada
Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive - Law360
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial - WTVB
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
A Look at Amgen Inc (AMGN) After 10.1% Decline -- GF Value $365. - GuruFocus
AMGN Looks 7.5% Overvalued on GF Value™ After Late-Stage Trial C - GuruFocus
Stocks to Watch Recap: Intel, Amgen, Qualcomm, Rigetti - WSJ
Amgen slides 10% amid olpasiran read-through concerns (AMGN:NASDAQ) - Seeking Alpha
AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market - Barron's
AMGN Looks 8.2% Overvalued on GF Value™ - GuruFocus
Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study - Reuters
Amgen: Why Rivals' Cholesterol Drug Failure Is Bad News For The Pharma (Rating Downgrade) - Seeking Alpha
Amgen Drops 9.0% Amid Sector-Wide Selling - AlphaStreet
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - Benzinga
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today - Benzinga
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% - Yahoo Finance
Amgen, Salesforce Share Losses Contribute To Dow's 525-Point Fall - Moomoo
What's Going On With Amgen Stock Tuesday? - Benzinga
Amgen caught in the crossfire of Novartis' failure - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownHere's Why - MarketBeat
Amgen (NASDAQ:AMGN): What’s Driving the Fresh Market Buzz? - Kalkine Media
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday - Yahoo Finance
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
Why Amgen Stock Is Down 8.7% And What's Next After Lp(a) Drug Doubts - simplywall.st
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone - marketscreener.com
Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis - TradingKey
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $400 - GuruFocus
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly - qz.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen (NASDAQ:AMGN) Receives "Neutral" Rating from Cantor Fitzgerald - MarketBeat
1.23%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):